The effect of oral magnesium, alone or as an adjuvant to sotalol, after cardioversion in patients with persistent atrial fibrillation

European Heart Journal

Volumn 21, Issue 14, 2000, Pages 1177-1185

  Frick, M ^a   Darpo B ^c   Ostergren J ^b   Rosenqvist, M ^c  

^a STOCKHOLM SÖDER HOSPITAL   (Sweden)

^b Departments of Medicine   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Arrhythmias; Atrial fibrillation; Cardioversion; Magnesium; Sotalol

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; MAGNESIUM HYDROXIDE; SOTALOL; T EMGESAN;

ADULT; AGED; ARTICLE; CARDIOVERSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SINUS RHYTHM;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DOUBLE-BLIND METHOD; ELECTRIC COUNTERSHOCK; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; MAGNESIUM HYDROXIDE; MALE; MIDDLE AGED; RECURRENCE; SAFETY; SOTALOL;

EID: 0034661786     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1999.1989     Document Type: Article

References (34)

1. Benjamin EJ, Wolf PA, D'Agostino RB. Impact of atrial fibrillation on the risk of death: The Framingham study. Circulation. 98:1998;946-952.
2. Lown B. Electrical reversion of cardiac arrhythmias. Br Heart J. 29:1962;469-489.
3. Coplen SE, Antman EM, Belin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for the maintenance of sinus rhythm after cardioversion. Circulation. 82:1990;1106-1116.
4. Sopher SM, Camm AJ. Atrial fibrillation: maintenance of sinus rhythm versus rate control. Am J Cardiol. 77:1996;24-37.
5. Juul-Möller S, Edvardsson N, Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation. 82:1990;1932-1939.
6. Reimold SC, Cantillon CO, Friedman PL, Antman EM. Propafenone versus sotalol for suppression of recurrent symtomatic atrial fibrillation. Am J Cardiol. 71:1993;558-563.
7. Kulick DL, Hong R, Ryzen E. Electrophysiologic effects of intravenous magnesium in patients with normal conduction systems and no clinical evidence of cardiac disease. Am Heart J. 115:1988;367-373.
8. DiCarlo LA, Morady F, Buitleir M, Krol RB, Schurig L, Annesley TM. Effects of magnesium sulphate on cardiac conduction and refractoriness in humans. J Am Coll Cardiol. 7:1986;1356-1362.
9. Perticone F, Ceravalo R, Costa R, Mattioli PL. Electrophysiologic effects of magnesium sulphate infusion in patients with cardiac conduction defects. J Am Coll Nutrition. 11:1992;405-409.
10. Gullestad L, Birkeland K, Molstad P, Hoyer MM, Vanberg P, Kjekshus J. The effect of magnesium versus verapamil on supraventricular arrhythmias. Clin Cardiol. 16:1993;429-434.
11. Moran JL, Gallagher J, Peake SL, Cunningham DN, Salagaras M, Leppard P. Parenteral magnesium sulphate versus amiodaron in therapy of atrial tachyarrhythmias: a prospective, randomized study. Critical Care Med. 23:1995;1816-1824.
12. Singh RB, Manmohan MD, Dube KP, Singh VP. Serum magnesium in atrial fibrillation. Acta Cardiol. 3:1976;221-226.
13. DeCarli C, Sprouse G, Larosa JC. Serum magnesium levels in symtomatic atrial fibrillation and their relation to rhythm control by intravenous digoxin. Am J Cardiol. 57:1986;956-959.
14. Reinhart R, Marx J, Broste S, Haas R. Myocardial magnesium: Relation to labatory and clinical variables in patients undergoing cardiac surgery. J Am Coll Cardiol. 17:1991;651-656.
15. Schweiger I, Kopel ME, Finlayson DC. Magnesium and postoperative dysrhythmias in patients after cardiac surgery. J Thoracic Anesthesiology. 3:1989;18.
16. Fanning W, Thomas C, Roach A, Tomichek R, Alford W, Stoney W. Prophylaxis of atrial fibrillation with magnesium sulfate after coronary artery bypass grafting. Ann Thorac Surg. 52:1991;529-533.
17. Coulquhoun I, Berg G, El-Fiky M, Hurle A, Fell G, Wheathly D. Arrhythmia orophylactics after coronary artery surgery. A randomised controlled trial of intravenous magnesium chloride. Eur J Cardiothorac Surg. 10:1993;520-523.
18. Parikka H, Toivonen L, Pellinen T, Verkala K, Järvinen A, Nieminen S. The influence of intravenous magnesium sulphate on the occurrence of atrial fibrillation after coronary artery bypass operation. Eur Heart J. 14:1993;251-258.
19. Lewis RV, Tregaskis B, McLay J, McDevitt DG. Oral magnesium reduces ventricular ectopy in digitalised patients with chronic atrial fibrillation. Eur J Clin Pharmacol. 38:1990;107-110.
20. Bashir Y, Staunton H, Mckenna W, Ward D, Camm A. Controlled trial of magnesium chloride supplementation in chronic heart failure. Eur Heart J. 12:1991;76.
21. cinterval of the electrocardiogram during open heart surgery. Canad Anaesth Soc J. 4:1981;329-333.
22. Van Gelder IC, Crinjs HJ, Van Gilst WH, Verwer R, Lie KI. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation. Am J Cardiol. 68:1991;41-46.
23. Wesley RC, Haines DE, Lerman B, Dimarco JP, Cramton RS. Effect of magnesium sulphate on supraventricular tachycardia. Am J Cardiol. 63:1989;1129-1131.
24. Hohnloser SH, Van de Loo A, Baedecker F. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: Prospective comparison of sotalol versus quinidine. J Am Coll Cardiol. 26:1995;852-858.
25. Van Gelder IC, Crinjs HJ, Tieleman RG. Success of serial cardioversion therapy and safety of oral anticoagulation. Arch Intern Med. 156:1996;2585-2592.
26. Chun SH, Sager PT, Stevenson WG, Nadamanee K, Middlekauf HR, Singh BN. Long term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol. 76:1995;47-50.
27. Wijfells MCEF, Kirchof CJHJ, Dorland R, Allesie MA. AF begets AF: a study in awake chronically instrumented goats. Circulation. 92:1995;1954-1968.
28. De Simone A, Stabile G, Vitale DF. Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion. J Am Coll Cardiol. 34:1999;810-814.
29. MacNeil DJ, Davies KO, Deitcman D. Clinical safety profile of sotalol in the treatment of arrhythmias. Am J Cardiol. 72:1993;44A-50A.
30. Tzivoni A, Keren. Suppression of ventricular arrhythmias by magnesium. Am J Cardiol. 65:1990;1397-1399.
31. Brodsky MA, Orlov MV, Caparelli EV. Magnesium therapy in new-onset atrial fibrillation. Am J Cardiol. 73:1994;1227-1229.
32. Frick M, Östergren J, Rosenqvist M. The effects of iv magnesium on heart rate and heart rate variability in patients with chronic atrial fibrillation. Am J Cardiol. 84:1999;104-108.
33. Ralston, MA, Murnane, MR, Kelley, RE, Altschuld, RA, Unverferth, DV, Leier, CV, Magnesium content of serum, circulating mononuclear cells, skeletal muscle, and myocardium in congestive heart failure, Circulation, 80, 573, 80.
34. Giles TD, Chobain AV. Magnesium deficiency: a new cardiovascular risk factor. `Magnesium deficiency: A new cardiovascular risk factor in sudden death?'. 1990;Health Care Communications, Fort Lee. p. 1-24.